The pharmacokinetics of a 1-h paclitaxel infusion

Cancer Chemotherapy and Pharmacology

Volumn 45, Issue 6, 2000, Pages 463-470

  Mross, K ^a   Hollander N ^a   Hauns, B ^a   Schumacher, M ^a   Maier Lenz, H ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Paclitaxel; Pharmacokinetics; Toxicity

Indexed keywords

ANTINEOPLASTIC AGENT; PACLITAXEL;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG METABOLISM; GYNECOLOGIC CANCER; HEAD AND NECK CANCER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LUNG CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; DRUG EVALUATION; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; UTERINE NEOPLASMS;

EID: 0034067115     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800051020     Document Type: Article

References (37)

1. 1. Arbruck SG, Canetta R, Onetto N, Christian M (1993) Current dosage and schedule issues in the development of paclitaxel (Taxol). Semin Oncol 20: 31-39
2. 2. Bailer AJ, Piegorsch WW (1980) Estimating integrals using quadrature methods with an application in pharmacokinetics. Biometrics 46: 1201-1211
3. 3. Beijnen JH, Huizing MT, Bokkel Huinink WW ten, Veenhoff CHN, Vermorken JB, Giaccone G, Pinedo HM (1994) Bioanalysis, pharmacokinetics, and pharmacodynamics of the novel anticancer drug paclitaxel (Taxol). Semin Oncol 21: 53-62
4. 4. Berg SL, Cowan KH, Balis FM, Fisherman JS, Denicoff AM, Hillig M, Poplack DG, O'Shoughnessy JA (1994) Pharmacokinetics of Taxol and doxorubicin administered alone and in combination by continuous 72-h infusion. J Natl Cancer Inst 86: 143-145
5. 5. Brat DJ, Windebank AJ, Brimijoin S (1992) Emulsifier for intravenous cyclosporin inhibits neurite outgrowth, causes deficits in rapid axonal transport and leads to structural abnormalities in differentiating N1 E.115 neuroblastoma. J Pharmacol Exp Ther 261: 803-810
6. 6. Brouwer E, Verweij J, Hauns B, Loos WJ, Nooter K, Mross K, Stoter G, Sparreboom A (1998) Linearized colorimetric assay for Cremophor EL: application to pharmacokinetics after one-h paclitaxel infusions. Anal Biochem 261: 198-202
7. 7. Cortes JE, Pazdur R (1995) Docetaxel. J Clin Oncol 13: 2643-2655
8. 8. De Groen PC, Aksamit AJ, Rakela J, Forbes GS, Krom RAF (1997) Central nervous system toxicity after liver transplantation. New Engl J Med 317: 861-866
9. 9. Eisenhauer EA, Bokkel Huinink WW ten, Swenerton KD, Gianni L, Myles J, Burg MEL van der, Kerr I, Vermorken JB, Buser K, Colombo N, Bacon M, Santabarbara P, Onetto N, Winograd B, Canetta R (1994) European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol 12: 2654-2666
10. 10. Gianni L, Kearns CM, Giani A, Capri G, Vigano L, Locatelli A, Bonodonna G, Egorin MJ (1995) Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/ pharmacodynamic relationship in humans. J Clin Oncol 13: 180-190
11. 11. Gibaldi M (1969) Effect of mode of administration on drug distribution in a two-compartment open system. J Pharm Sci 58: 327-331
12. 12. Greco FA, Hainsworth JD (1997) Paclitaxel (1-h infusion) plus carboplatin in the treatment of advanced non-small cell lung cancer: results of a multicenter phase II study. Semin Oncol 24: S12-17
13. 13. Grem JL, Tutsch KD, Simon KJ, Alberti DB, Willson JK, Tormey DC (1987) Phase I study of Taxol administered as a short intravenous infusion daily for 5 days. Cancer Treat Rep 71: 1179-1181
14. 14. Hainsworth JD, Greco FA (1994) Paclitaxel administered by 1-h infusion. Cancer 74: 1377-1382
15. 15. Hainsworth JD, Thompson DS, Greco FA (1995) Paclitaxel by 1-h infusion: an active drug in metastatic non-small-cell lung cancer. J Clin Oncol 13: 1609-1614
16. 16. Holländer N, Mross K, Schumacher M (1998) The influence of different weighting schemes on the calculation of pharmacokinetic parameters for paclitaxel. Freiburg Center for Data Analysis and Modelling, Preprint No. 50
17. 17. Huizing MT, Keung ACF, Rosing H, Kuij V van der, Bokkel Huinink WW ten, Mandjes IM, Dubbelman AC, Pinedo HM, Beijnen JH (1993) Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. J Clin Oncol 11: 2127-2135
18. 18. Huizing MT, Vermorken JB, Rosing H, Bokkel Huinink WW ten, Mandjes I, Pinedo HM, Beijnen JH (1995) Pharmacokinetics of paclitaxel and three major metabolites in patients with advanced breast carcinoma refractory to anthracycline therapy treated with a 3-h paclitaxel infusion: a European Cancer Centre (ECC) trial. Ann Oncol 6: 699-704
19. 19. Kearns CM, Gianni L, Egorin M (1995) Paclitaxel pharmacokinetics and pharmacodynamics. Semin Oncol 22 [Suppl 6]: 16-23
20. 20. Klotz U, Kroemer HK (1991) The drug interaction potential of ranitidin. Pharmacol Ther 50: 233-244
21. 21. Mross K, Hauns B, Häring B, Bauknecht T, Meerpohl HG, Unger C, Maier-Lenz H (1998) Clinical phase I study with one-h infusion. Ann Oncol 9: 569-572
22. 22. Ohnishi A, Inoue N, Yamamoto T, Murai Y, Hori H, Tanaka I, Koga M, Akiyama T (1986) Ethylene oxide neuropathy in rats. Neurol Sci 74: 215-221
23. 23. Philip H, Schwartz CP (1989) The application of BASE SAS, SAS/STAT, and SAS/GRAPH software to the analysis and presentation of pharmacokinetic data. In: Proceedings of the SAS User's Group 14th International Conference. SAS Institute, Cary, NC. pp 1168-1172
24. 24. Rowinsky EK, Donehower RC (1995) Paclitaxel (Taxol). New Engl J Med 332: 1004-1014
25. 25. Rowinsky EK, Burke PJ, Karp JE, Tucker RW, Ettinger DS, Donehower RC (1989) Phase I and pharmacodynamic study of Taxol in refractory acute leukemias. Cancer Res 49: 4640-4647
26. 26. SAS Institute (1989) SAS/STAT user's guide, 6th/4th edition. SAS Institute, Cary, NC
27. 27. Seidman AD, Tiersten A, Hudis C, Gollup M, Barrett S, Yao TJ, Lepore J, Gilewski T, Currie V, Crown J, Hakes T, Baselga J, Skalrin N, Moynikan ME, Tong W, Egorin M, Kearns C, Spriggs D, Norton L (1995) Phase II trial of paclitaxel by 3-h infusion as initial and salvage chemotherapy for metastatic breast cancer. J Clin Oncol 13: 2575-2581
28. 28. Somogyi A, Muirhead M (1987) Pharmacokinetic interactions of cimetidine. Clin Pharm 12: 321-366
29. 29. Sonnichsen DS, Hurwitz CA, Pratt CB, Shuster JJ, Relling MV (1994) Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors. J Clin Oncol 12: 532-538
30. 30. Sparreboom A, Asperen J van, Mayer U, Schinkel AH, Smit JW, Meijer DK, Borst P, Nooijen WJ, Beijnen JH, Teilingen O van (1997) Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci USA 94: 2031-2035
31. 31. Spriggs DR, Tondini C (1992) Taxol administered as a 120 hour infusion. Invest New Drugs 10: 275-278
32. 32. Weiss R, Donehower RC, Wiernik PH, Ohnuma T, Gralla RJ, Trump DL, Baker JR, Echo DA van, Hoff DD von, Leyland-Jones B (1990) Hypersensitivity reactions from Taxol. J Clin Oncol 8: 1263-1268
33. 33. Wiernick PH, Schwartz EL, Einzig A, Strauman JJ, Lipton RB, Dutcher JP (1987) Phase I trial of Taxol given as 24-h infusion every 21 days: responses observed in metastatic melanoma. J Clin Oncol 5: 1232-1239
34. 34. Wiernick PH, Schwartz EL, Strauman JJ, Dutcher JP, Lipton RB, Paietta E (1987) Phase I clinical trial and pharmacokinetic study of Taxol. Cancer Res 47: 2486-2493
35. 35. Willey TA, Bekos EJ, Gaver RC, Duncan GF, Tay LK, Beijnen JH, Farmen RH (1993) High performance liquid chromatographic procedure for the quantitative determination of paclitaxel (Taxol) in human plasma. J Chromatogr 621: 231-238
36. 36. Windebank AJ, Blexrud MD, Groen PC de (1994) Potential neurotoxicity of the solvent vehicle for cyclosporin. J Pharmacol Exp Ther 268: 1051-1056
37. 37. Woodcock DM, Jefferson S, Linsenmeyer ME (1990) Reversal of the multidrug resistance phenotype with Cremophor EL, a common vehicle for water-insoluble vitamins and drugs. Cancer Res 50: 4199-4204